DK2328930T3 - Antistoffer rettet mod pyroglutamat-monocyt-kemoattraktant-protein-1 (mcp-1N1pE) - Google Patents

Antistoffer rettet mod pyroglutamat-monocyt-kemoattraktant-protein-1 (mcp-1N1pE) Download PDF

Info

Publication number
DK2328930T3
DK2328930T3 DK09782017T DK09782017T DK2328930T3 DK 2328930 T3 DK2328930 T3 DK 2328930T3 DK 09782017 T DK09782017 T DK 09782017T DK 09782017 T DK09782017 T DK 09782017T DK 2328930 T3 DK2328930 T3 DK 2328930T3
Authority
DK
Denmark
Prior art keywords
1n1pe
pyroglutamate
mcp
antibodies directed
chemoattractant protein
Prior art date
Application number
DK09782017T
Other languages
English (en)
Inventor
Holger Cynis
Hans-Ulrich Demuth
Kathrin Gans
Jens-Ulrich Rahfeld
Stephan Schilling
Sonja Kampfer
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Application granted granted Critical
Publication of DK2328930T3 publication Critical patent/DK2328930T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
DK09782017T 2008-08-20 2009-08-20 Antistoffer rettet mod pyroglutamat-monocyt-kemoattraktant-protein-1 (mcp-1N1pE) DK2328930T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9026408P 2008-08-20 2008-08-20
PCT/EP2009/060757 WO2010020669A1 (en) 2008-08-20 2009-08-20 Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)

Publications (1)

Publication Number Publication Date
DK2328930T3 true DK2328930T3 (da) 2015-03-30

Family

ID=41259004

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09782017T DK2328930T3 (da) 2008-08-20 2009-08-20 Antistoffer rettet mod pyroglutamat-monocyt-kemoattraktant-protein-1 (mcp-1N1pE)

Country Status (12)

Country Link
US (3) US8518406B2 (da)
EP (1) EP2328930B1 (da)
JP (1) JP5819194B2 (da)
AU (1) AU2009284092B2 (da)
CA (1) CA2734800C (da)
DK (1) DK2328930T3 (da)
ES (1) ES2533493T3 (da)
IL (1) IL210866A (da)
NZ (1) NZ591187A (da)
PL (1) PL2328930T3 (da)
WO (1) WO2010020669A1 (da)
ZA (1) ZA201100658B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090024811A (ko) 2006-06-23 2009-03-09 아보트 러보러터리즈 히스타민 h3 수용체 조절제로서의 사이클로프로필 아민 유도체
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
CA2789091A1 (en) * 2010-02-18 2011-08-25 Probiodrug Ag Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
RU2476880C1 (ru) * 2011-08-25 2013-02-27 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации Способ диагностики гестоза тяжелой степени
WO2015085171A1 (en) * 2013-12-06 2015-06-11 Adventist Health Systems/Sunbelt, Inc. Role of mcp-1 in relapse of acute myeloid leukemia after hematopoietic stem cell transplantation
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US10980739B2 (en) 2016-12-14 2021-04-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2023213400A1 (en) * 2022-05-05 2023-11-09 Institute For Research In Biomedicine Antibodies against chemokines, method for identifying said antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4504733A (en) * 1984-05-15 1985-03-12 Sybron Corporation Dry bath temperature control
US5229580A (en) * 1992-06-09 1993-07-20 Automated Biosystems, Inc. Block for holding multiple sample tubes for automatic temperature control
US6191398B1 (en) * 1999-09-10 2001-02-20 Barnstead/Thermolyne Corporation Dry bath temperature control and method
US7309693B2 (en) * 2000-05-26 2007-12-18 Kensuke Egashira Preventives and remedies for pulmonary hypertension
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds
WO2003068920A2 (en) * 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Humanized gm-csf antibodies
WO2003072736A2 (en) * 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
WO2004016769A2 (en) 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
EP1538207B1 (en) 2002-09-12 2010-06-02 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Human anti-human mcp-1 antibody and antibody fragment thereof
WO2006125201A2 (en) 2005-05-19 2006-11-23 Centocor, Inc. Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
PE20110071A1 (es) * 2005-05-19 2011-01-31 Centocor Inc Anticuerpos anti-mcp-1, composiciones y metodos
CA2630344C (en) * 2006-03-23 2015-04-28 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US20080056957A1 (en) * 2006-09-01 2008-03-06 Chemglass, Inc. Segmented reaction blocks for supporting vials of different sizes for chemical synthesis on a hot plate stirrer

Also Published As

Publication number Publication date
US20130302835A1 (en) 2013-11-14
IL210866A (en) 2015-11-30
AU2009284092B2 (en) 2016-05-19
ES2533493T3 (es) 2015-04-10
JP5819194B2 (ja) 2015-11-18
IL210866A0 (en) 2011-04-28
WO2010020669A1 (en) 2010-02-25
US20150361167A1 (en) 2015-12-17
CA2734800A1 (en) 2010-02-25
EP2328930A1 (en) 2011-06-08
US20100119478A1 (en) 2010-05-13
CA2734800C (en) 2021-02-09
NZ591187A (en) 2012-07-27
EP2328930B1 (en) 2014-12-24
AU2009284092A1 (en) 2010-02-25
US9157918B2 (en) 2015-10-13
JP2012500016A (ja) 2012-01-05
PL2328930T3 (pl) 2015-05-29
US8518406B2 (en) 2013-08-27
ZA201100658B (en) 2012-05-01

Similar Documents

Publication Publication Date Title
DK2328930T3 (da) Antistoffer rettet mod pyroglutamat-monocyt-kemoattraktant-protein-1 (mcp-1N1pE)
DK2262836T3 (da) Antistof mod CSF-1R
FI20095006A (fi) Kompaktit monimuuntajat
BRPI0912585A2 (pt) compósito acústico
DK2277021T3 (da) Acoustic holography
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
DK2338287T3 (da) Transducersystem
DK2346754T3 (da) Trådplade-transportbånd
ATE530578T1 (de) Antikörper gegen il-17a
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BRPI0907237A2 (pt) Anticorpo anti-cldn6
BRPI0914743A2 (pt) estrutura
BRPI0905620A2 (pt) Transdutor magnético
DK2248360T3 (da) Vibrationstone differentiering
BRPI0907122A2 (pt) Piridoindóis (1-azinona) substituídos
BRPI0917195A2 (pt) estrutura compósita curada-plana
BRPI0909633A2 (pt) anticorpos anti-tyrp1
IT1392670B1 (it) Iniettore
FR2935129B1 (fr) Pedalier compact
BRPI0912769A2 (pt) anticorpos anti-pirb
FI20086154A0 (fi) Katalyyttirakenne
FI20085899A0 (fi) Puu-Metalli-komposiittirakenne
SE0800657L (sv) Tandborste
BRPI0918173A2 (pt) estrutura em degraus
FR2929436B1 (fr) Piano